Shilpa Medicare Ltd. (SHILPAMED) — Tipsheet

Shilpa Medicare partners with Orion for Nivolumab biosimilar in Europe

Tipsheet Editorial — Tue, 30 Jun 2026 10:26:19 GMT

Shilpa Biologicals will develop and supply the biosimilar; Orion handles EU regulatory and marketing. Originator Nivolumab had $4.1B in European sales in 2025.

What’s new

Shilpa Biologicals signs co-development and supply deal with Orion for a Nivolumab biosimilar.
Shilpa will lead development and be exclusive long-term supplier; Orion holds marketing rights in Europe.
Milestone payments plus supply revenue, but deal value undisclosed.

Why it matters

Nivolumab is a blockbuster immuno-oncology drug nearing loss of exclusivity in Europe. For Shilpa, a mid-cap with ₹11,179 cr market cap and trailing revenue of ₹437 cr, locking in a partner with Orion's commercial reach opens a material revenue stream in biosimilars, complementing its recent ADC facility and biologics CDMO push.

What we’re watching

Regulatory milestones and timeline for European approval.
Visibility on deal economics when Shilpa discloses milestones.
Integration with Shilpa's Dharwad biologics capacity and ongoing CDMO ramp.

The full read

Shilpa Medicare's subsidiary has signed a co-development and supply deal with Finnish pharma Orion Corporation for a Nivolumab biosimilar. Shilpa Biologicals will develop and manufacture at its Dharwad facility; Orion holds the marketing rights and will be the Marketing Authorisation holder in Europe. The target market: originator Nivolumab's $4.1 billion in European sales as it loses exclusivity. Shilpa gets milestone payments plus long-term supply revenue—undisclosed. That's the prize. The deal builds on Shilpa's recent ₹437 cr quarterly revenue and its expansion into biologics CDMO, including a new ADC facility. For a mid-cap with ₹11,179 cr market cap, the partnership validates manufacturing capabilities and opens a high-value pipeline. The open question is how much of that $4.1B market the pair can capture.

Primary source: BSE · NSE

Shilpa Medicare commissions ADC facility, targets global CDMO play

Tipsheet Editorial — Wed, 24 Jun 2026 09:05:22 GMT

The Dharwad plant is fully operational and entering GMP qualification; the company aims to become a cost-competitive CDMO partner for oncology drug makers.

What’s new

Shilpa Biologicals commissioned an ADC GMP facility in Dharwad.
Facility is fully operational and entering GMP qualification for US FDA & EMA.
Shilpa joins a handful of Indian firms with fully integrated ADC development and manufacturing capabilities.

Why it matters

Antibody-drug conjugates are a high-growth oncology segment, and Shilpa's 25-year high-potency chemistry heritage gives it a credible entry point. However, the lack of disclosed capex or immediate revenue contracts means the payoff is still distant.

What we’re watching

First commercial contract wins with global biotech or pharma clients.
US FDA/EMA inspection outcomes at the Dharwad facility.
Any quantified capex or revenue guidance for ADC manufacturing in upcoming calls.

The full read

Shilpa Medicare has moved from selling off-patent injectables to building a biologics CDMO business. The commissioning of its ADC facility at Dharwad (fully operational and entering GMP qualification for US FDA and EMA) puts it in a small group of Indian firms that can handle the entire ADC production chain from payload synthesis to conjugation. Managing Director Vishnukant Bhutada called it a decisive step. But the announcement carries no capex figure, no revenue guidance, and no signed client. For a company with ₹437 cr quarterly revenue and a ₹11,562 cr market cap, the ADC bet is a long-term story, not a near-term catalyst. The recent €7M Spanish biotech investment and the shelved European trial suggest Shilpa is repositioning toward higher-complexity molecules. The real test: whether the Dharwad facility can win initial commercial contracts from global oncology innovators in the next few quarters.

Primary source: BSE · NSE

Shilpa Medicare buys 30% of Spanish biotech for €7M, chases a brain-cancer therapy

Tipsheet Editorial — Wed, 03 Jun 2026 09:31:39 GMT

Its unit Shilpa Biocare acquires a minority stake in Gate2Brain, gaining manufacturing rights for a candidate with orphan drug status from the FDA and EMA.

What’s new

Shilpa Biocare is buying 30.4% of Spanish biotech Gate2Brain for €7M.
The deal gives Shilpa exclusive manufacturing and regulatory support rights for G2B-002, a brain-cancer therapy.
G2B-002 has orphan drug designation from both the FDA and EMA for two childhood brain cancers.

Why it matters

The deal gives Shilpa a foothold in central-nervous-system drug delivery via a proprietary peptide shuttle. But the investment is only about 0.6% of its market cap, so it's a long-biotech-horizon bet rather than a near-term revenue driver. The real payoff, if any, is years away.

What we’re watching

Whether Shilpa can translate the manufacturing rights into a meaningful commercial role if G2B-002 succeeds.
Progress toward first-in-human trials by FY28.
How the €7M investment fits into Shilpa's broader pipeline spending.

The full read

Shilpa Medicare is paying €7 million for a 30.4% stake in Spanish biotech Gate2Brain. The prize isn't the equity. It's the exclusive manufacturing and regulatory support rights for G2B-002, a therapy for diffuse intrinsic pontine glioma and pediatric glioblastoma that uses a peptide shuttle to cross the blood-brain barrier. Both the FDA and EMA have granted it orphan drug status, a designation for rare diseases that can speed regulatory review. The catch: first-in-human trials aren't expected to start until FY28, and the €7 million outlay is only about 0.6% of Shilpa's market cap. This is a pipeline option, not a revenue catalyst. For a mid-cap drug maker, the move signals interest in advanced delivery tech, but the commercial verdict is years out.

Primary source: BSE · NSE

Shilpa Medicare drops Aflibercept Europe trial, delays alopecia drug

Tipsheet Editorial — Tue, 26 May 2026 13:51:49 GMT

The company shelved a costly European trial for one biologic and pushed back a Phase I for another, even as Q4 FY26 hit record revenue.

What’s new

Shilpa Medicare will not pursue European Phase III trials for Aflibercept, citing high costs.
Phase I studies for alopecia treatment SMLTOP09 delayed; now expected to start in FY27.
Adjusted ROCE improved to 17.4% from 4% in FY23, excluding biologics investments.

Why it matters

Shedding the Aflibercept program and delaying SMLTOP09 narrows the pipeline right when revenue is peaking. It saves development cash but pushes meaningful biologic revenue further out, making the core API and formulation businesses carry the story alone for now.

What we’re watching

Whether the SMLTOP09 Phase I actually starts in FY27 as guided.
FY27 growth trajectory for European formulations and the CDMO business.
Any moves to backfill the dropped Aflibercept program.

The full read

Shilpa Medicare is cutting its losses. On the Q4 FY26 call, CEO Keshav Bhutada said the company will not pursue European Phase III trials for Aflibercept, citing prohibitive costs. Separately, the Phase I study for its experimental alopecia treatment, SMLTOP09, has been pushed back and is now expected to start in FY27. Both decisions narrow the near-term clinical pipeline, even as the company posted record quarterly revenue of ₹439 crore and a 40% rise in EBITDA. CFO Alpesh Dalal pointed to improving fundamentals, with adjusted ROCE reaching 17.4% from just 4% in FY23. Management offered no FY27 numbers, only talk of healthy growth in European formulations and the CDMO business. The result is a company in transition. Cash is flowing from the core business while meaningful biologic revenue gets pushed further out.

Primary source: BSE · NSE

Shilpa Medicare kills European Aflibercept push, defers Unicycive revenue to FY28

Tipsheet Editorial — Fri, 22 May 2026 17:23:08 GMT

Strong FY26 results couldn't mask a conference call full of delays. Pipeline programs are sliding and the margin target is off the table.

What’s new

Shilpa Medicare abandoned European Phase III trials for Aflibercept due to cost.
Human studies for alopecia drug SMLTOP09 have been postponed.
Revenue from Unicycive Therapeutics pushed out to FY28.

Why it matters

Three pipeline setbacks in one call erased the narrative of a clean FY26. Scrapping the European Aflibercept program removes a major potential revenue stream from the near-term view, while deferring Unicycive revenue leaves a gap. Management's refusal to guide on its own 35% EBITDA margin target makes the pipeline losses harder to stomach.

What we’re watching

Whether Shilpa finds a partner or new strategy for Aflibercept outside Europe.
Revised timelines for SMLTOP09 human studies and their revenue impact.
How the company will close the FY27 revenue gap without Unicycive.

The full read

FY26 was strong. Revenue up 30%, EBITDA up 40%. But the conference call told a different story. Shilpa Medicare killed its European push for Aflibercept, postponed human studies for SMLTOP09, and deferred Unicycive revenue to FY28. Three pipeline hits in one call. Management then refused to guide on its own 35% EBITDA margin target, calling it ambitious. The financials are solid. The future just got smaller and later.

Primary source: BSE · NSE

Shilpa Medicare profit hits ₹108 cr as pharma operations turn around

Tipsheet Editorial — Fri, 22 May 2026 14:58:46 GMT

Consolidated net profit grew sevenfold in the March quarter while the company moved to buy a 28% stake in Neo Green Power.

What’s new

Q4 consolidated revenue rose 32% to ₹437 cr.
Standalone profit swung to ₹71 cr from a ₹5.6 cr loss last year.
The board approved a 28% stake in Neo Green Power for ₹4.44 cr.

Why it matters

The jump from a standalone loss to a ₹71 cr profit marks a shift from prior-year volatility. While associate contributions helped, the core business turnaround suggests that internal consolidation is now affecting cash flow.

What we’re watching

Sustainability of service income without one-time gains.
Integration results from the merged wholly-owned subsidiaries.
Impact of shifting the registered office from Karnataka to Maharashtra.

The full read

Shilpa Medicare finished FY26 with a change in performance. Consolidated revenue rose 32% to ₹437 crore for the March quarter. Net profit reached ₹108 crore against ₹14.5 crore a year ago, aided by an ₹18.2 crore share of profit from a foreign associate and gains from a joint venture stake sale. The standalone results confirm the shift, moving from a ₹5.6 crore loss in Q4FY25 to a ₹71 crore profit. The company is using its cash position to pay a 60 paise dividend and put ₹4.44 crore into a 28% stake in Neo Green Power. Moving the registered office from Karnataka to Maharashtra marks a change for the board. The next test is whether the pharma business maintains this profit growth without non-operating income.

Primary source: BSE · NSE

Shilpa Medicare profit triples to ₹243 cr

Tipsheet Editorial — Fri, 22 May 2026 14:58:26 GMT

Consolidated profits surged behind an improved operating performance and a one-time stake sale, while management targets captive energy savings.

What’s new

Consolidated net profit tripled to ₹243 cr from ₹78.29 cr in FY25.
Standalone profit rose to ₹132.97 cr, supported by a 25% revenue increase.
Board proposed a final dividend of 60 paise per share.

Why it matters

The jump in bottom-line growth stems partly from a one-time joint venture stake sale, tempering the apparent momentum. While the dividend signals cash-flow confidence, these results largely tracked market expectations set during recent quarterly updates.

What we’re watching

The integration of the captive renewable power project into operating margins.
Shareholder response to the proposed relocation of the registered office to Maharashtra.
Sustainability of revenue growth without non-recurring gains.

The full read

Shilpa Medicare wrapped up FY26 with a massive expansion in consolidated net profit, which hit ₹243.33 crore against ₹78.29 crore the year prior. Revenue from operations climbed 20% to reach ₹1,539 crore. The standalone business contributed ₹132.97 crore to that bottom line, nearly doubling from its ₹67.89 crore result in FY25. Much of the consolidated gain relies on a one-time windfall from a joint venture stake sale, and the market had largely priced these numbers in during previous calls. Management is now pivoting toward captive power costs by picking up a 28% stake in a renewable energy firm for ₹4.44 crore. They are also clearing the decks to move the registered office from Karnataka to Maharashtra. The results are solid, but the next phase for the company depends on core performance rather than the asset-divestment boost that defined this year’s earnings.

Primary source: BSE · NSE